Evidence map›Paper›PMID 30319320›Full record

ArticleAdvanced functional materials2017

Encapsulating a Hydrophilic Chemotherapeutic into Rod-like Nanoparticles of a Genetically Encoded Asymmetric Triblock Polypeptide Improves its Efficacy.

Jayanta Bhattacharyya, Isaac Weitzhandler, Shihan Bryan Ho, Jonathan R McDaniel, Xinghai Li, Lei Tang, Jinyao Liu, Mark Dewhirst, Ashutosh Chilkoti

Abstract read
In one paragraph

Article in Advanced functional materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Peptide-based coacervates in therapeutic applications.Frontiers in bioengineering and biotechnology · 2022
    Review
  14. Article
  15. Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy inClinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  16. Article
  17. Review
  18. Polymeric nanobiotics as a novel treatment for mycobacterial infections.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  19. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.Small (Weinheim an der Bergstrasse, Germany) · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jayanta BhattacharyyaDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Isaac WeitzhandlerDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Shihan Bryan HoDuke-NUS Graduate Medical School Singapore, Singapore 169857, Singapore.
Jonathan R McDanielDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Xinghai LiDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Lei TangDepartment of Mechanical Engineering and Materials Science, Duke University, 144 Hudson Hall, Durham, North Carolina 27708, USA.
Jinyao LiuDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Mark DewhirstDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27708, USA.
Ashutosh ChilkotiDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.

Funding

Thermally Targeted Drug Delivery by Elastin BiopolymersR01EB000188 · NIBIB · DUKE UNIVERSITY · PI CHILKOTI, ASHUTOSH · 2002 to 2015
$3.9M
Thermally Triggered Multivalent Targeting of TumorsR01EB007205 · NIBIB · DUKE UNIVERSITY · PI CHILKOTI, ASHUTOSH · 2007 to 2015
$2.7M
NIBIB NIH HHS R01 EB000188NIBIB NIH HHS R01 EB007205
6 · The paper itself

Abstract

Encapsulating hydrophilic chemotherapeutics into the core of polymeric nanoparticles can improve their therapeutic efficacy by increasing their plasma half-life, tumor accumulation and intracellular uptake, and by protecting them from premature degradation. To achieve these goals, we designed a recombinant asymmetric triblock polypeptide (ATBP) that self-assembles into rod-shaped nanoparticles, and which can be used to conjugate diverse hydrophilic molecules, including chemotherapeutics, into their core. These ATBPs consist of three segments: a biodegradable elastin-like polypeptide, a hydrophobic Tyrosine-rich segment, and a short Cysteine-rich segment, that spontaneously self-assemble into rod-shaped micelles. Covalent conjugation of a structurally diverse set of hydrophilic small molecules, including a hydrophilic chemotherapeutic -gemcitabine- to the Cysteine residues also leads to formation of nanoparticles over a range of ATBP concentrations. Gemcitabine-loaded ATBP nanoparticles have significantly better tumor regression compared to free drug in a murine cancer model. This simple strategy of encapsulation of hydrophilic small molecules by conjugation to an ATBP can be used to effectively deliver a range of water-soluble drugs and imaging agents in vivo.

Indexed as

asymmetric triblock polypeptidecolon cancergemcitabinehydrophilic drug deliverynanoparticle

Identifiers

PMID30319320
PMCPMC6178977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.